Press Release: Sanofis Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma

Summary

Sanofis Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma

Source: manilatimes.net

(0)

AI News Q&A (Free Content)

This content is freely available. No login required. Disclaimer: Following content is AI generated from various sources including those identified below. Always check for accuracy. No content here is an advice. Please use the contact button to share feedback about any inaccurate content generated by AI. We sincerely appreciate your help in this regard.

Q1: What is Sarclisa, and how is it used in the treatment of multiple myeloma?

A1: Sarclisa, also known as Isatuximab, is a monoclonal antibody used to treat multiple myeloma. It works by targeting the CD38 antigen on myeloma cells, helping the body's immune system to attack these cancerous cells. It is typically used in patients who have not responded to other treatments.

Q2: What are the common side effects associated with Sarclisa?

A2: Common side effects of Sarclisa include neutropenia (low neutrophil count), infusion reactions, pneumonia, upper respiratory tract infections, diarrhea, and bronchitis. These are typical of monoclonal antibody therapies and are generally managed with supportive care.

Q3: How does the subcutaneous formulation of Sarclisa benefit patients compared to the intravenous version?

A3: The subcutaneous formulation of Sarclisa allows for more convenient administration, potentially reducing infusion-related reactions and the time patients spend receiving treatment. This can improve the overall treatment experience and adherence for patients with multiple myeloma.

Q4: What role does the CHMP play in the approval of new drug formulations like Sarclisa's subcutaneous version?

A4: The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the European Medicines Agency's opinions on all questions concerning medicines for human use. Their recommendation for approval is a critical step towards making new drug formulations available to patients across the European Union.

Q5: How has Sanofi been involved in the development and distribution of Sarclisa?

A5: Sanofi, a global healthcare leader, developed Sarclisa in part through its acquisition of Genzyme, a biotechnology company. Sanofi has utilized its extensive resources and expertise to advance Sarclisa's development and distribution, ensuring its availability in numerous countries.

Q6: What are monoclonal antibodies, and how do they contribute to cancer treatment?

A6: Monoclonal antibodies are lab-produced molecules that can mimic the immune system's ability to fight off harmful pathogens such as viruses. In cancer treatment, they are designed to bind to specific targets on cancer cells, marking them for destruction by the immune system or directly inhibiting cancer cell growth.

Q7: What potential impact could the EU approval of Sarclisa's subcutaneous formulation have on patients with multiple myeloma?

A7: The EU approval of Sarclisa's subcutaneous formulation could significantly enhance treatment accessibility and patient comfort. This approval would provide an alternative administration route that is less invasive than intravenous infusions, thereby improving patients' quality of life and treatment adherence.